Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Medpace Holdings, Inc.    MEDP


News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Medpace Holdings, Inc. : Buying pressure

share with twitter share with LinkedIn share with facebook
03/05/2020 | 08:28am EDT
long trade under condition
Conditional Order Terminated
Entry price : 109.9$ | Target : 150$ | Stop-loss : 95$ | Cancellation Level : 85$ | Potential : 36.49%
Medpace Holdings, Inc. shares have recently benefited from a buyers' comeback, which was accompanied by a rise in volumes and volatility. This situation suggests a continuation of the upward dynamic.
Investors should benefit from the breakout of the $ 109.9 level to target the $ 150.
Medpace Holdings, Inc. : Medpace Holdings, Inc. : Buying pressure
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
  • The company has solid fundamentals for a short-term investment strategy.

  • Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 40% by 2022.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
  • The group usually releases upbeat results with huge surprise rates.
  • Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • For the past twelve months, EPS forecast has been revised upwards.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • The tendency within the weekly time frame is positive above the technical support level at 70.16 USD

  • The stock is close to a major daily resistance at USD 101.95, which should be gotten rid of so as to gain new appreciation potential.
  • The company benefits from high valuations in earnings multiples.
Stocks mentioned in the article
ChangeLast1st jan.
AT HOME GROUP INC. 2.76% 5.96 Delayed Quote.8.36%
JUST GROUP PLC 2.25% 49.06 Delayed Quote.-37.90%
LETS HOLDINGS GROUP CO., LTD. -1.85% 11.64 End-of-day quote.92.72%
LOOK HOLDINGS INCORPORATED -2.42% 685 End-of-day quote.-45.29%
MEDPACE HOLDINGS, INC. -0.96% 98.18 Delayed Quote.16.80%
RISE, INC. -3.13% 31 End-of-day quote.3.33%
WILL GROUP, INC. -2.52% 618 End-of-day quote.-50.64%

Nicolas Aleksy
© MarketScreener.com 2020
share with twitter share with LinkedIn share with facebook

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials (USD)
Sales 2020 832 M - -
Net income 2020 83,5 M - -
Net cash 2020 196 M - -
P/E ratio 2020 44,7x
Yield 2020 -
Capitalization 3 473 M 3 473 M -
EV / Sales 2019
EV / Sales 2020 3,94x
Nbr of Employees 3 600
Free-Float 75,7%
Upcoming event on MEDPACE HOLDINGS, INC.
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 88,40 $
Last Close Price 98,18 $
Spread / Highest target -6,29%
Spread / Average Target -9,96%
Spread / Lowest Target -15,5%
EPS Revisions
August James Troendle Chairman, President & Chief Executive Officer
Susan E. Burwig Executive Vice President-Operations
Jesse J. Geiger Chief Financial & Accounting Officer
Daniel O'Leary Senior Vice President-Medical Department
Steven B. Johnson SVP-Scientific & Strategic Development
Sector and Competitors
1st jan.Capitalization (M$)
LONZA GROUP52.43%42 546
CELLTRION, INC.79.28%36 149
MODERNA, INC.220.09%24 344